NAYA's Lead Astatine-211 Targeted Alpha Therapy, NY-703, Aiming to Enter Clinical Trials for Residual & Metastatic HCC in 2026
MIAMI, FL and LANSING, MI / ACCESS Newswire / August 21, 2025 / NAYA Therapeutics ("NAYA"), a clinical-stage biopharmaceutical company dedicated to pioneering the next generation of cancer therapies through the development of astatine-211 (²¹¹At) targeted alpha therapies (TATs) and bifunctional antibodies today announced that it has entered into a partnership agreement with Ionetix, a cyclotron and technology company providing full-service radioisotope production and end-to-end radiopharmaceutical manufacturing solutions.
"We are delighted to partner with Ionetix and leverage their integrated contract research and manufacturing capabilities to help deploy a decentralized hub & spoke supply chain for astatine-211 therapeutics, a model we believe is the key to unlocking broad patient access," commented Dr. Daniel Teper, CEO of NAYA Therapeutics. "NAYA is planning to announce additional partnerships in Europe and Asia to accelerate clinical development and commercialization and is committed to the development of ²¹¹At targeted alpha therapies to address the challenges of residual & metastatic disease in cancer patients, starting with NY-703, our GPC3-targeting ²¹¹At candidate in hepatocellular carcinoma (HCC)."
"Astatine-211 has the potential to emerge as a preferred isotope for use in targeted alpha therapies" added David Eve, Ionetix's VP of Medical Affairs. "Its unique characteristics can enable safer, more effective, and more accessible cancer treatments for patients. By combining Ionetix's proven isotope production expertise and commitment to building a commercial-scale national supply chain with NAYA's clinical leadership and plans to deploy a localized network of satellite GMP drug manufacturing sites, we are well-positioned to accelerate the growth of astatine-211 targeted alpha therapies."
About the US Astatine-211 Network
Ionetix, leveraging its proprietary cyclotron technology platform, will expand ²¹¹At production capacity across the United States by establishing a network of multiple Regional Alpha Isotope ManufacturingFacilities ("Regional Facilities"), each strategically located to maximize patient access.
NAYA will extend this infrastructure by deploying satellite GMP drug manufacturing sites to extend the final clinical-dose production of ²¹¹At therapies for distribution to local treatment centers.
About Ionetix
Ionetix, a leader in cyclotron technology, is a vertically integrated radioisotope manufacturer providing access to scarce radioisotopes, including ²¹¹At, and offering full-service contract drug manufacturing and specialized logistics. IONETIX is leading the way and is establishing the first North American clinical and commercial scale supply of of alpha-emitting radioisotopes from its new cyclotron facility in Lansing, MI which can already supply preclinical and early clinical-stage quantities of astatine-211 throughout North America.
About NAYA Therapeutics
NAYA Therapeutics is pioneering the next generation of cancer therapies, aiming to unlock deeper, more durable responses in patients not responding to current standard-of-care. NAYA's pipeline harnesses the transformational potential of two synergistic modalities: astatine-211 (²¹¹At) targeted alpha therapies & bifunctional antibodies, with an initial focus on hepatocellular carcinoma (HCC).
About NY-703
NY-703 is a GPC3-targeting astatine-211 (²¹¹At) targeted alpha therapy for the treatment of residual & metastatic hepatocellular carcinoma (HCC), aiming to achieve initial clinical data in 2026. It consists of a GPC3-antibody fragment F(ab')2 conjugated to an astatine-211 isotope through an optimized proprietary linker. Hepatocellular Carcinoma is a rapidly-growing cancer with an estimated one million new patients every year. Up to 75% of HCC patients treated with surgery and/or immunotherapy relapse within 5 years, often due to the presence of metastases and minimal residual disease (MRD).
NAYA Media & Investor Contact
Lyn Falconio
lyn@nayatx.com
NAYA Media & Investor Contact
David Eve
deve@ionetix.com
SOURCE: NAYA Therapeutics
View the original press release on ACCESS Newswire